Investment Summary |
|
|---|---|
| Date | 2021-12-01 |
| Target | Oui Therapeutics |
| Sector | Life Science |
| Investor(s) |
Athyrium Capital Management
Polaris Partners |
| Deal Type | Venture |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Asset Manager |
|---|---|
| Founded | 2008 |
| PE ASSETS | 3.7B USD |
| Size | Large |
| Type | Sector Focused |
Athyrium Capital Management is a large asset manager focused on the healthcare sector. Athyrium invests in a wide range of financial instruments including royalties, structured credit, and equities as well as select special situations. Athyrium Capital was established in 2008 and is headquartered in New York City.
| DEAL STATS | # |
|---|---|
| Overall | 42 of 44 |
| Sector (Life Science) | 21 of 22 |
| Type (Venture) | 5 of 5 |
| State (Connecticut) | 1 of 1 |
| Country (United States) | 39 of 39 |
| Year (2021) | 3 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-11-19 |
InnovaCare Health
Orlando, Florida, United States InnovaCare Health improves the lives of patients and physicians through innovative solutions for value-based healthcare. Throughout its 20+ year history, InnovaCare Health has owned, operated, and managed an integrated portfolio of medical groups, health plans, medical service organizations, clinical networks, and more. InnovaCare Health was founded in 1998 is based in Orlando, Florida. |
Sell | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-05-25 |
uMotif
London, United Kingdom uMotif's mission is to put patients at the center of clinical research. Designed with patients for patients, the uMotif patient-first eClinical platform powers site-based to fully decentralised clinical, real-world, and post-marketing research. By engaging patients and healthcare professionals, uMotif is trusted by global pharmaceutical companies, biotechs, CROs, and academic institutions to capture large volumes of eCOA/ePRO, symptom, and wearable device data. uMotif was founded in 2012 and is based in London, United Kingdom. |
Buy | - |
| Category | Growth Capital Firm |
|---|---|
| Founded | 1996 |
| PE ASSETS | 5.0B USD |
| Size | Large |
| Type | Sector Agnostic |
Polaris Partners is primarily a seed, first round, and early stage venture capital investor in information technology and life science businesses. However, Polaris also focuses on private equity investments in established companies. In this area, Polaris targets high growth middle market companies in industries including technology, healthcare, digital media, consumer products and services, and business services. The firm's investments include minority growth equity investments, recapitalizations with liquidity, and leveraged buyouts. Polaris Partners was formed in 1996 and has offices in Seattle, Washington and Waltham, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 80 of 87 |
| Sector (Life Science) | 33 of 39 |
| Type (Venture) | 51 of 57 |
| State (Connecticut) | 1 of 1 |
| Country (United States) | 72 of 78 |
| Year (2021) | 16 of 17 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-11-12 |
Ankyra Therapeutics
Boston, Massachusetts, United States Ankyra Therapeutics, a company developing cancer therapies based on tumor localized immune potentiating agents that boost anti-tumor immune responses, Ankyra was founded in 2019 and is headquartered in Boston, Massachusetts. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-12-07 |
Freenome
South San Francisco, California, United States Freenome develops blood-based tests for early cancer detection, applying its proprietary multiomics platform, deep expertise in molecular biology and advanced machine learning. Freenome was founded in 2014 and is based in South San Francisco, California. |
Buy | - |
